person · Reporting owner

Tammenoms Bakker Juliet

Disclosed activity across 20 companies

Tapewire entity: 36915
SEC CIK: 0001431159

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aimmune Therapeutics, Inc.AIMT · Entity 145931	10% owner	February 22, 2018	February 26, 2018
Axonics, Inc.AXNX · Entity 86004	Director	September 18, 2020	September 22, 2020
Ceribell, Inc.CBLL · Entity 4994	Director	June 02, 2026	June 04, 2026
Eargo, Inc.EAR · Entity 94112	Director · 10% owner	May 17, 2021	May 19, 2021
Inozyme Pharma, Inc.INZY · Entity 77717	10% owner	April 19, 2022	April 21, 2022
Lexeo Therapeutics, Inc.LXEO · Entity 5687	10% owner	November 07, 2023	November 10, 2023
Molecular Templates, Inc.MTEM · Entity 85987	10% owner	August 28, 2020	September 01, 2020
RxSight, Inc.RXST · Entity 1226	Director	June 17, 2026	June 18, 2026
Tourmaline Bio, Inc.TALS · Entity 15643	10% owner	May 11, 2021	May 11, 2021
Vaxcyte, Inc.PCVX · Entity 1164	10% owner	June 11, 2020	June 11, 2020
Vera Therapeutics, Inc.VERA · Entity 4358	10% owner	February 06, 2023	February 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aimmune Therapeutics, Inc.

Report date February 22, 2018 · Filed February 26, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,651	Reported balance After 2018-02-22 transaction · row 1 1 source row Row 1 · 2018-02-22 · Purchase · Acquired 9,375 · Balance 16,651 F1: The shares were purchased in the Issuer's underwritten public offering closed on February 26, 2018.
Common StockSEC Table I · non-derivative	IndirectBy LVP2	6,013,134	Reported balance Holding disclosure · report date 2018-02-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 6,013,134 F2: Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person is a managing member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were purchased in the Issuer's underwritten public offering closed on February 26, 2018.

F2: Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person is a managing member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

Axonics, Inc.

Report date September 18, 2020 · Filed September 22, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,500	Reported balance After 2020-09-18 transaction · row 1 1 source row Row 1 · 2020-09-18 · Sale · Disposed 9,167 · Balance 3,500 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.36 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners III, L.P.	1,955,333	Reported balance Holding disclosure · report date 2020-09-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,955,333 F2: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III"), is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. The Reporting Person, who is a member of the Issuer's board of directors, and Patrick G. Enright are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers"), and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,026	Reported balance Holding disclosure · report date 2020-09-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,026 F3: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such share except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.36 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III"), is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. The Reporting Person, who is a member of the Issuer's board of directors, and Patrick G. Enright are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers"), and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such share except to the extent of her pecuniary interest therein.

Ceribell, Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,284	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,838 · Balance 23,284 F1: Represents restricted stock units ("RSUs").
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners IV, L.P.	2,475,110	Reported balance Holding disclosure · report date 2026-06-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,475,110 F2: The securities are held by Longitude Venture Partners IV, L.P. ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment, and dispositive power over the securities held by LVPIV. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCPIV and may each be deemed to share voting, investment, and dispositive power over the securities held by LVPIV. Each of LCPIV, Ms. Tammenoms Bakker, and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs").

F2: The securities are held by Longitude Venture Partners IV, L.P. ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment, and dispositive power over the securities held by LVPIV. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCPIV and may each be deemed to share voting, investment, and dispositive power over the securities held by LVPIV. Each of LCPIV, Ms. Tammenoms Bakker, and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

Eargo, Inc.

Report date May 17, 2021 · Filed May 19, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,918,691	Reported balance After 2021-05-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-05-17 · Other · Disposed 1,000,000 · Balance 1,918,691 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners. F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. The Reporting Person and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,008	Reported balance After 2021-05-17 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-05-17 · Other · Acquired 1,504 · Balance 3,008 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members F4: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	7,016	Reported balance After 2021-05-17 transaction · row 3 1 source row Row 3 · 2021-05-17 · Other · Acquired 3,508 · Balance 7,016 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners.

F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. The Reporting Person and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members

F4: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Inozyme Pharma, Inc.

Report date April 19, 2022 · Filed April 21, 2022

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners III, L.P.	4,174,379	Reported balance After 2022-04-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-04-19 · Purchase · Acquired 1,355,000 · Balance 4,174,379 F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Lexeo Therapeutics, Inc.

Report date November 07, 2023 · Filed November 10, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners IV, L.P.	2,567,100	Last balance in matching sequence After 2023-11-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2023-11-07 · Conversion · Acquired 1,793,429 · Balance 1,793,429 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2023-11-07 · Conversion · Acquired 319,126 · Balance 2,112,555 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 3 · 2023-11-07 · Purchase · Acquired 454,545 · Balance 2,567,100 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A convertible preferred stockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners IV, L.P.	0	Reported balance After 2023-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-07 · Conversion · Disposed 18,999,999 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B convertible preferred stockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners IV, L.P.	0	Reported balance After 2023-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-07 · Conversion · Disposed 2,906,148 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Molecular Templates, Inc.

Report date August 28, 2020 · Filed September 01, 2020

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2020-08-28 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2020-08-28 · Sale · Disposed 2,447 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2020-08-28 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2020-08-28 · Sale · Disposed 1,049 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,495	Reported balance Holding disclosure · report date 2020-08-28 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 3,495 F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners III, L.P.	3,199,035	Reported balance Holding disclosure · report date 2020-08-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 3,199,035 F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").

F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

RxSight, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	85,183	Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 85,183 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,548	Reported balance Holding disclosure · report date 2026-06-17 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,548 F3: These securities are held by a trust. The Reporting Person, a member of the Issuer's board of directors, is the Investment Trustee of such trust and may be deemed to share voting, investment and dispositive power with respect to such securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

F3: These securities are held by a trust. The Reporting Person, a member of the Issuer's board of directors, is the Investment Trustee of such trust and may be deemed to share voting, investment and dispositive power with respect to such securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Tourmaline Bio, Inc.

Report date May 11, 2021 · Filed May 11, 2021

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners III, L.P.	3,220,775	Last balance in matching sequence After 2021-05-11 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2021-05-11 · Conversion · Acquired 2,985,775 · Balance 2,985,775 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2021-05-11 · Purchase · Acquired 235,000 · Balance 3,220,775 F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners III, L.P.	0	Reported balance After 2021-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-05-11 · Conversion · Disposed 1,308,410 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners III, L.P.	0	Reported balance After 2021-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-11 · Conversion · Disposed 1,271,027 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners III, L.P.	0	Reported balance After 2021-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-11 · Conversion · Disposed 406,338 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering.

Vaxcyte, Inc.

Report date June 11, 2020 · Filed June 11, 2020

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	Not disclosed	Reported balance Holding disclosure · report date 2020-06-11 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	Not disclosed	Reported balance Holding disclosure · report date 2020-06-11 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	Not disclosed	Reported balance Holding disclosure · report date 2020-06-11 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	Not disclosed	Reported balance Holding disclosure · report date 2020-06-11 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration.

F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration.

F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration.

Vera Therapeutics, Inc.

Report date February 06, 2023 · Filed February 08, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Longitude Venture Partners IV, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,714,285	Reported balance After 2023-02-06 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2023-02-06 · Purchase · Acquired 1,714,285 · Balance 1,714,285 F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	3,429,927	Reported balance Holding disclosure · report date 2023-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,429,927 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (9)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

89bio, Inc.

Report date November 16, 2020 · Filed November 18, 2020

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., ENRIGHT PATRICK G

Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,750,877	Reported balance After 2020-11-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-16 · Other · Disposed 850,000 · Balance 1,750,877 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,973	Reported balance After 2020-11-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-11-16 · Other · Acquired 2,973 · Balance 2,973 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,080	Reported balance After 2020-11-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-11-16 · Other · Acquired 2,080 · Balance 2,080 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	891	Reported balance After 2020-11-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2020-11-16 · Other · Acquired 891 · Balance 891 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6: These shares are held directly by Ms. Bakker.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F6: These shares are held directly by Ms. Bakker.

Aptinyx Inc.

Report date June 25, 2018 · Filed June 26, 2018

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P.

Section 16 reporting ended · disclosed 2018-06-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy: Longitude Venture Partners II, L.P.	3,190,079	Last balance in matching sequence After 2018-06-25 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2018-06-25 · Conversion · Acquired 1,047,450 · Balance 1,047,450 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein. Row 2 · 2018-06-25 · Conversion · Acquired 1,197,076 · Balance 2,244,526 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein. Row 3 · 2018-06-25 · Conversion · Acquired 795,553 · Balance 3,040,079 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein. Row 4 · 2018-06-25 · Purchase · Acquired 150,000 · Balance 3,190,079 F4: On June 25, 2018, Longitude Venture II purchased 150,000 shares of Common Stock of the Issuer at a price of $16.00 per share in the Issuer's initial public offering. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein.
Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy: Longitude Venture Partners II, L.P.	0	Reported balance After 2018-06-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-06-25 · Conversion · Disposed 28,895,188 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy: Longitude Venture Partners II, L.P.	0	Reported balance After 2018-06-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-06-25 · Conversion · Disposed 33,022,786 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy: Longitude Venture Partners II, L.P.	0	Reported balance After 2018-06-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-06-25 · Conversion · Disposed 21,946,301 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.

F2: This statement is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this statement (but all of whom have ceased to share beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the filing of this statement and, as a result, are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended). The shares reported in this statement are held directly by Longitude Venture II. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II.

F3: Ms. Bakker is a managing member of Longitude Capital II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude Venture II. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its or her pecuniary interest therein.

F4: On June 25, 2018, Longitude Venture II purchased 150,000 shares of Common Stock of the Issuer at a price of $16.00 per share in the Issuer's initial public offering.

COLLEGIUM PHARMACEUTICAL, INC

Report date December 08, 2017 · Filed December 12, 2017

Jointly reported with Longitude Capital Partners, LLC, ENRIGHT PATRICK G, Longitude Capital Associates, L.P., Longitude Venture Partners L.P.

Section 16 reporting ended · disclosed 2017-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LVP	2,276,222	Reported balance After 2017-12-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-12-08 · Sale · Disposed 980,350 · Balance 2,276,222 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy LCA	45,620	Reported balance After 2017-12-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-12-08 · Sale · Disposed 19,650 · Balance 45,620 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.

CORCEPT THERAPEUTICS INC

Report date December 15, 2016 · Filed December 19, 2016

Section 16 reporting ended · disclosed 2016-12-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	133,539	Reported balance After 2016-12-15 transaction · row 1 1 source row Row 1 · 2016-12-15 · Gift · Disposed 70,671 · Balance 133,539
Common StockSEC Table I · non-derivative	IndirectBy LVP	10,740,720	Reported balance Holding disclosure · report date 2016-12-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,740,720 F1: Reflects holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA"). Ms. Bakker is a managing member of Longitude Capital Partners, LLC, the sole general partner of LVP and LCA. Ms. Bakker disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy LCA	215,282	Reported balance Holding disclosure · report date 2016-12-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 215,282 F1: Reflects holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA"). Ms. Bakker is a managing member of Longitude Capital Partners, LLC, the sole general partner of LVP and LCA. Ms. Bakker disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA"). Ms. Bakker is a managing member of Longitude Capital Partners, LLC, the sole general partner of LVP and LCA. Ms. Bakker disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of her pecuniary interest therein.

KALA BIO, Inc.

Report date July 25, 2017 · Filed July 27, 2017

Jointly reported with Longitude Capital Partners II, LLC, ENRIGHT PATRICK G, Longitude Venture Partners II, L.P.

Section 16 reporting ended · disclosed 2017-07-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners II, L.P.	2,270,946	Last balance in matching sequence After 2017-07-25 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-07-25 · Conversion · Acquired 2,055,946 · Balance 2,055,946 F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering. Row 2 · 2017-07-25 · Purchase · Acquired 215,000 · Balance 2,270,946 F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	0	Reported balance After 2017-07-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-07-25 · Conversion · Disposed 10,707,985 · Balance 0 F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.

RAPID MICRO BIOSYSTEMS, INC.

Report date February 04, 2026 · Filed February 06, 2026

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., ENRIGHT PATRICK G

Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectHeld by Longitude Prime Fund, L.P.	0	Reported balance After 2026-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-02-04 · Sale · Disposed 49,000 · Balance 0 F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	IndirectHeld by Longitude Venture Partners II, L.P.	4,029,245	Reported balance Holding disclosure · report date 2026-02-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,029,245 F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Sierra Oncology, Inc.

Report date April 27, 2022 · Filed April 29, 2022

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., ENRIGHT PATRICK G, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P.

Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2022-04-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-04-27 · Other · Disposed 175,000 · Balance 0 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2022-04-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2022-04-27 · Other · Disposed 1,964,771 · Balance 0 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,023	Reported balance After 2022-04-27 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2022-04-27 · Other · Acquired 5,023 · Balance 5,023 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6: These shares are held directly by Juliet Tammenoms Bakker.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,152	Reported balance After 2022-04-27 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2022-04-27 · Other · Acquired 2,152 · Balance 2,152 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	7,175	Reported balance After 2022-04-27 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2022-04-27 · Other · Acquired 7,175 · Balance 7,175 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8: These shares are held directly by Patrick G. Enright.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,611	Reported balance After 2022-04-27 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2022-04-27 · Other · Acquired 588 · Balance 5,611 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6: These shares are held directly by Juliet Tammenoms Bakker.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,404	Reported balance After 2022-04-27 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2022-04-27 · Other · Acquired 252 · Balance 2,404 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	8,015	Reported balance After 2022-04-27 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2022-04-27 · Other · Acquired 840 · Balance 8,015 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8: These shares are held directly by Patrick G. Enright.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.

F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.

F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F6: These shares are held directly by Juliet Tammenoms Bakker.

F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

F8: These shares are held directly by Patrick G. Enright.

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

Tricida, Inc.

Report date July 02, 2018 · Filed July 03, 2018

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., ENRIGHT PATRICK G

Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectLongitude Venture Partners II, L.P.	2,888,155	Last balance in matching sequence After 2018-07-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-07-02 · Conversion · Acquired 2,431,511 · Balance 2,431,511 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2018-07-02 · Conversion · Acquired 456,644 · Balance 2,888,155 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectLongitude Venture Partners II, L.P	3,019,734	Reported balance After 2018-07-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-07-02 · Purchase · Acquired 131,579 · Balance 3,019,734 F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	0	Reported balance After 2018-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-02 · Conversion · Disposed 9,677,419 · Balance 0 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners II, L.P.	0	Reported balance After 2018-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-02 · Conversion · Disposed 1,817,447 · Balance 0 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.

F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.

F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Venus Concept Inc.

Report date February 14, 2020 · Filed March 05, 2020

Section 16 reporting ended · disclosed 2020-03-05. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 06, 2023 Filed Feb 8, 2023 19:40 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,714,285	$7.00	$11,999,995.00	Disclosure SEC source: 0000899243-23-004349 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,714,285 F1 · ownership.nature: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
June 02, 2022 Filed Jun 4, 2022 00:24 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	10,349	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034396 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,708 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 2, 2022. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	840	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 8 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,015 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	252	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 7 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,404 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	588	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 6 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,611 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	7,175	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,175 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	2,152	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,152 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	5,023	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,023 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	1,964,771	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4 · ownership.nature: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	175,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2 · ownership.nature: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
April 19, 2022 Filed Apr 21, 2022 18:04 UTC	Inozyme Pharma, Inc. INZY · Entity 77717	PurchaseCommon Stock	1,355,000	$3.69	$4,999,950.00	Disclosure SEC source: 0000899243-22-015325 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,174,379 F1 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
February 10, 2022 Filed Apr 5, 2022 11:24 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	333,333	$15.00	$4,999,995.00	Disclosure SEC source: 0000899243-22-013598 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,429,927 F1 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
February 02, 2022 Filed Feb 2, 2022 21:25 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	175,000	$27.00	$4,725,000.00	Disclosure SEC source: 0000899243-22-004271 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 175,000 F1 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LPF and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP. Each of Mr. Enright, Ms. Tammenoms Bakker and Dr. Richardson disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
January 25, 2022 Filed Jan 27, 2022 21:23 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherSeries B Warrants · Derivative	1,477,125	$13.20 Strike: $13.20	$19,498,050.00	Disclosure SEC source: 0000899243-22-003502 · doc4.xml · derivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 487,451 shares Expires 2022-04-10 F2 · shares: Consists of 1,477,125 Series B Warrants held by LVP III which are exercisable for an aggregate of 487,451 shares of Common Stock. F1 · ownership.nature: These securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
January 25, 2022 Filed Jan 27, 2022 21:23 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	487,451	$13.20	$6,434,353.20	Disclosure SEC source: 0000899243-22-003502 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,964,771 F1 · ownership.nature: These securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	ConversionSeries H Preferred Stock · Derivative	8,177	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 10 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 8,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	Tax withholdingSeries H Preferred Stock · Derivative	28,125	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 9 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,177 Underlying: Common Stock · 28,125 shares Expires not disclosed F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	Exercise / conversionSeries H Preferred Stock · Derivative	36,302	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 8 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 36,302 Underlying: Common Stock · 36,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	Exercise / conversionWarrant (right to buy) · Derivative	36,302	$0.00 Strike: $12.40	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 7 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series H Preferred Stock · 36,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F5 · derivative.expiration_date: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	ConversionSeries H Preferred Stock · Derivative	242,013	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 6 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 242,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	ConversionSeries G Preferred Stock · Derivative	1,613,423	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 5 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,613,423 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	PurchaseCommon Stock	500,000	$16.00	$8,000,000.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 4 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 500,000 F4 · ownership.nature: Shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LPP and may be deemed to share voting and investment power over the securities held by LPF. LPF, LPP and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	PurchaseCommon Stock	125,000	$16.00	$2,000,000.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 3 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,988,613 F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	ConversionCommon Stock	1,863,613	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 2 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,863,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:41 UTC	RxSight, Inc. RXST · Entity 1226	PurchaseCommon Stock	12,500	$16.00	$200,000.00	Disclosure SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,359 Read SEC document
July 30, 2021 Filed Aug 3, 2021 00:17 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	5,859	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031109 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,859 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following July 30, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionCommon Stock Warrant · Derivative	129,032	$0.00 Strike: $0.05	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 9 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 129,032 Underlying: Class A Common Stock · 129,032 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries B1 Warrant · Derivative	645,160	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 8 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series B1 Preferred Stock · 645,160 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionCommon Stock Warrant · Derivative	500,000	$0.00 Strike: $0.05	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 7 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries A1 Warrant · Derivative	2,500,000	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 6 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series A1 Preferred Stock · 2,500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries C1 Preferred Stock · Derivative	2,291,665	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 5 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 458,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries B1 Preferred Stock · Derivative	5,654,529	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 4 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,130,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries A1 Preferred Stock · Derivative	8,774,007	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 3 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,754,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	PurchaseClass A Common Stock	150,000	$20.00	$3,000,000.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 150,000 F2 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting, investment and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionClass A Common Stock	3,344,038	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 3,407,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	ConversionSeries C Preferred Stock · Derivative	2,187,504	$0.00	$0.00	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · derivative · entry 3 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 2,187,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	909,090	$11.00	$9,999,990.00	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,096,594 F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	ConversionClass A Common Stock	2,187,504	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,187,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 17, 2021 Filed May 19, 2021 20:58 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	3,508	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019943 · doc4.xml · nonDerivative · entry 3 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,016 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members Read SEC document
May 17, 2021 Filed May 19, 2021 20:58 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	1,504	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019943 · doc4.xml · nonDerivative · entry 2 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,008 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members F4 · ownership.nature: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
May 17, 2021 Filed May 19, 2021 20:58 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019943 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,918,691 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners. F2 · ownership.nature: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. The Reporting Person and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
May 11, 2021 Filed May 11, 2021 20:29 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	ConversionSeries B Preferred Stock · Derivative	406,338	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 406,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
May 11, 2021 Filed May 11, 2021 20:29 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	ConversionSeries A-1 Preferred Stock · Derivative	1,271,027	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,271,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
May 11, 2021 Filed May 11, 2021 20:29 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	ConversionSeries A Preferred Stock · Derivative	1,308,410	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,308,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
May 11, 2021 Filed May 11, 2021 20:29 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	PurchaseCommon Stock	235,000	$17.00	$3,995,000.00	Disclosure SEC source: 0000899243-21-019166 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,220,775 F3 · price: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
May 11, 2021 Filed May 11, 2021 20:29 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	ConversionCommon Stock	2,985,775	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-019166 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,985,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:04 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	3,508	$0.00	$0.00	Disclosure SEC source: 0000899243-21-016026 · doc4.xml · nonDerivative · entry 3 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,508 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members. Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:04 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	1,504	$0.00	$0.00	Disclosure SEC source: 0000899243-21-016026 · doc4.xml · nonDerivative · entry 2 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,504 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members. F4 · ownership.nature: These shares are held by a trust. The Reporting Person is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:04 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-016026 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,918,691 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. The Reporting Person and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:11 UTC	89bio, Inc. ETNB · Entity 73682	OtherCommon Stock	891	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 891 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6 · ownership.nature: These shares are held directly by Ms. Bakker. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.